Psychiatry

Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.


OBJECTIVE: To compare the efficacy of AXS-07 with gepants (rimegepant, ubrogepant, zavegepant) approved for acute migraine treatment in the United States using a network meta-analysis (NMA).

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M. Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder. BMC Psychiatry. 2024 Sep 10;24(1):605. doi: 10.1186/s12888-024-06034-


Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.


Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.


DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882


BACKGROUND: Patient perspectives of living with borderline personality disorder (BPD) are not traditionally captured in the literature. To overcome this gap, we explored participants’ experiences with BPD to gain a better understanding of symptoms and impacts related to the condition.

DiBenedetti D, Huang M-Y, Kosa K, Suthoff E, Bonthapally V, Lasser R, Pollack M, Doherty J, Mak C, Cutler AJ, Mattingly GW. Assessing individuals' experiences with zuranolone for major depressive disorder: qualitative interviews with participants from the open-label shoreline study. Poster presented at the 2023 ASCP Annual Meeting; May 31, 2023. Miami Beach, FL.


Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687


Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia or bipolar I disorder. Poster presented at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 30, 2023. Miami Beach, FL.


Huang MY, Counts N, Smith A, Brister T, Sweeney C, McSorley D, Suthoff E, Parikh S. Perspectives on the unmet need in the treatment of major depressive disorder: results from a patient survey. Poster presented at the Psych Congress 2022; September 17, 2022. New Orleans, LA.


BACKGROUND: Major depressive disorder (MDD) is a common brain health disorder that affects at least 1 in 5 individuals in the United States (US) during their lifetime. Adults with MDD were surveyed to rate the importance of desirable attributes associated with a new therapy for MDD.

Huang MY, Smith A, Brister T, Counts N, Sweeney C, McSorley D, Suthoff E, Parikh S. Report from a national survey of depression treatment: patient experience on antidepressant medications for major depressive disorder. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Pharm. 2022 Oct; 28(10-a):S59-60.


Subscribe to Psychiatry

How Can We Help You?